Immune-Related Genomic Schizophrenic Subtyping Identified in DLPFC Transcriptome

Area of Science:

• Neuroscience
• Psychiatry
• Immunology

Background:

• Schizophrenia exhibits significant heterogeneity, suggesting diagnostic subtyping could reveal underlying pathobiology.
• Increased inflammation is implicated in a subset of schizophrenia patients, but findings are inconsistent, possibly due to treating the disorder as a single entity.

Purpose of the Study:

• To investigate biological differences between molecularly defined schizophrenia subgroups.
• To explore the role of neuroinflammation in distinct schizophrenia subtypes.

Main Methods:

• Post-mortem dorsolateral prefrontal cortex tissue samples from schizophrenia patients were analyzed.
• Gene expression data from publicly available datasets were used to segregate patients into Type 1 and Type 2 subgroups.
• Expression of genes related to complement cascade, glial activation, inflammatory mediators, blood-brain barrier integrity, chemokines, and immune cell infiltration was examined.

Main Results:

• Schizophrenia patients were successfully segregated into Type 1 and Type 2 groups based on gene expression.
• Type 2 schizophrenics displayed widespread abnormal gene expression across multiple neuroinflammation pathways.
• These widespread neuroinflammatory changes were not observed in Type 1 schizophrenics.

Conclusions:

• Molecular subtyping of schizophrenia is crucial for understanding its diverse pathobiology.
• Immune-related pathways are significantly involved in a specific subset of schizophrenia (Type 2).
• These findings support the hypothesis that neuroinflammation plays a key role in a portion of schizophrenia cases.